Global Multi-Omics Market Growth is set to be driven by emerging demands for Personalized Medicine

Contact Us
121/7E Avenue Franklin Roosevelt 1050 Brussels
Brussels 1050 
Phone:+ 32 498 86 80 79

The demand for personalised medicine, technical developments, a favourable funding environment, the increased prevalence of cancer and genetic disorders, and expanding pharmaceutical and biotech R&D expenditure are projected to be the main drivers of the next phase of growth.

The term “omics” has emerged as the new mantra in molecular research. It is a biological sciences research topic whose name ends with the suffix -omics. Numerous areas of research can be classified as omics such as genomics, transcriptomics, proteomics and metabolomics.

Genomics studies genes and their function. Genomics finds application in drug discovery and development, diagnostics & therapeutic decision-making, agriculture, animal research and other applications.

Transcriptomics studies mRNAs. It is widely used for clinical diagnostics, drug discovery, toxicogenomics and other applications.

Proteomics studies proteins. It is used for clinical diagnosis of cancer, infectious diseases, cardiovascular diseases, immune diseases, neurological disorders, diabetes, etc. and drug discovery.

Metabonomics studies small molecules involved in cellular metabolism. It is a powerful research tool that is currently being applied to various aspects of drug and biomarker discovery, toxicology research, nutrigenomics and other applications

The interpretation of molecular complexity and variations at several levels, including the genome, transcriptome, proteome, and metabolome, is necessary for a complete knowledge of human health and disease. With the development of sequencing technology, biology has depended increasingly on the data generated at these levels, sometimes known as “multi-omics” data. Availability of Multi-Omics data has revolutionized the field of medicine and biology. Understanding causal relationships at various levels of cellular organisation is facilitated by data integration across many platforms (genomics, transcriptomics, proteomics, and metabolomics). It offers unparalleled opportunities to understand the underlying biology of complex diseases such as cancer.

“The advent of multi-omics is turning scientists into molecular detectives and helping them to delve into the depths of disease. It allows researchers and scientists to probe the more complex and transient molecular changes that underpin the course of disease and responses to treatment, helping them better select the right drug target”. – Senior Director, Data Sciences & Quantitative Biology, Tier I Pharmaceutical & Biotechnology Company

Explore Premium Report on Multi-omics Market @

Single-cell Analysis Enters the Multi-Omics Era
A cell’s condition can be defined by the interplay between its genome, epigenome, transcriptome, and proteome. Multi-Omics technologies for single cells have evolved as a result of the advancement of these omics technologies, allowing them to capture data from numerous omic layers within the same cell. Profiling multiple omic layers makes it possible to capture a more complete set of information about each cell than is possible from any single omic layer alone. Single-cell multi-omics are considered to be more powerful than a stand-alone omics because they more accurately represent the comprehensive network of interactions that underlies cellular functions.

Single-cell multi-Omics technologies are set to take center stage in biomedical research as it enables the characterization of cells and tissues at an unparalleled molecular and architectural resolution.

Competitive Landscape Analysis of Multi-omics Market
Some of the key players operating in the global multi-omics market are 10x Genomics, Bio-Techne Corporation, Fluidigm Corporation, Bio-Rad Laboratories, Inc., NanoString, Mission Bio, BD Biosciences, Thermo Fisher Scientific Inc., among others.

For More Detailed Insights, Contact Us @

About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79